Revance Therapeutics Inc
RVNC
Market Cap$381.02M
Close$
$6.05
65.7% upside
Current Fair Value
65.7% upsideUndervalued by 65.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $381.02 Million |
|---|---|
| Enterprise Value | $847.26 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.83 |
| Beta | 0.95 |
| Outstanding Shares | 104,212,891 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.1 |
|---|---|
| PEG | 2.79 |
| Price to Sales | 1.83 |
| Price to Book Ratio | -1.83 |
| Enterprise Value to Revenue | 3.43 |
| Enterprise Value to EBIT | -5.18 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | -3.22 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Revance Therapeutics Inc
CEO: Mark Foley